Resectable Stage Early-Onset Biliary Tract Cancer: Survival and Prognostic Scoring (EOB-RS and EOB-OS) in Turkish Patients (TOG/GI-SAFRADJU-2502-EO)
Akkus, Erman, Kayaalp, Mehmet, Ergozoglu, Muzeyyen Asli, Koc Kus, Ilgin, Bayram, Dogan, Kilictas, Bilgesah, Ayvaz Guneyin, Emel, Kalem, Ali, Temizyurek, Haydar, Catli, Mehmet Mutlu, Akarca, Mehmet Sinan, Mildanoglu, Maral Martin, Turhan, Gorkem, Kara, Mahmut, Arak, Haci, Arslan Tan, Feyza, Pacaci, Burak, Yesilyurt, Berkay, Akdogan, Orhun, Cetin, Emine Bihter, Celik, Selahattin, Keskin Uzundere, Fatma, Sahin, Elif, Sadak Ocal, Zehra, Seker Can, Lamia, Koylu, Bahadir, Fidan, Mehmet Cem, Kaplan Tuzun, Esmanur, Sakalar, Teoman, Sertesen Camoz, Elif, Yuksel, Haydar Cagatay, Balcik, Onur Yazdan, Peker, Pinar, Yilmaz, Mehmet, Ala Enli, Seymanur, Kolemen, Erdem, Oyucu Orhan, Sibel, Duzkopru, Yakup, Ersoy, Mustafa, Akin Telli, Tugba, Yilmaz, Mesut, Ilhan, Yusuf, Yildirim, Atila, Cosar, Ramazan, Urun, Muslih, Onder, Arif Hakan, Araz, Murat, Bayram, Ertugrul, Yesil Cinkir, Havva, Alkan, Ali, Gurbuz, Mustafa, Avci, Nilufer, Paksoy Turkoz, Fatma, Kara, Ismail Oguz, Kose, Fatih, Unek, Ilkay Tugba, Bilici, Ahmet, Bal, Oznur, Yalcin, Suayib, Yasar, Hatime Arzu
PURPOSE Early-onset gastrointestinal cancers are concerning entities globally, yet early-onset biliary tract cancers (EOBTCs) are understudied. Early-stage disease is crucial for young patients' survival. METHODS TOG/GI-SAFRADJU (ClinicalTrials.gov identifier: NCT06975917) is a multicenter, hospital-based, registry initiative of the Turkish Oncology Group, including patients with resected BTCs. Early-onset was defined as a diagnosis at age <50 years. Characteristics and survival of EOBTC and non-EOBTC were compared. Among patients with EOBTC, prognostic factors for recurrence-free survival (RFS) and overall survival (OS) were analyzed. Risk scores were assigned on the basis of hazard ratios. RESULTS Six hundred seventeen patients from 44 centers were included. 12.6% (n = 78) were EOBTC. R1 resection rate was significantly higher among EOBTC (37.1% v 25.7%, P = .038). Adjuvant treatments did not differ between EOBTC and non-EOBTC. Among patients who received adjuvant chemotherapy, RFS (13.9 months [95% CI, 11.4 to 22.1] v 15.9 months [95% CI, 13.6 to 18.9], P = .947) and OS (35.6 months [95% CI, 28.0 to 81.4] v 31.3 months [95% CI, 27.8 to 44.3], P = .670) were similar between EOBTC and non-EOBTC groups. Among patients with EOBTC, R1-resection and high CA19-9 levels were associated with shorter RFS, and gallbladder localization and high CA19-9 were associated with shorter OS in adjusted analyses. Using these factors, risk scores early-stage EOBTC RFS score (EOB-RS) for RFS and early-stage EOBTC OS score (EOB-OS) for OS were formed, each including three ranks. Both scores significantly ordered the prognosis of patients with EOBTC (EOB-RS, [0 points]: 22.7 months, [1 or 2]: 10.3 months, [3]: 5.7 months, P < .001, EOB-OS: [0]: 110.9 months, [1 or 2]: 29.6 months, [3]: 10.1 months, P < .001). CONCLUSION Resected EOBTC patients showed survival comparable to older counterparts receiving surgery/adjuvant therapy. This study suggests a potential risk scoring system for early-stage EOBTC, pending validation.
- Dergi
- JCO GLOBAL ONCOLOGY
- Yıl
- 2026
- Cilt
- 12
- eISSN
- 2687-8941
- DOI
- 10.1200/GO-25-00655
- WoS UID
- WOS:001729904500001